Comment by jrapdx3
3 days ago
I get what you're saying but I think there's a problem, gobs of common drugs have 2D6 as a metabolic pathway. Increasing 2D6 inhibition puts recipients at greater risk of serious adverse events or drug toxicity. Can't say much about pharmacodynamics of candidate compounds, that remains to be determined experimentally in live subjects including animal models and possibly phase 1 trials.
In any case I appreciate the interesting ideas in your comment and the article.
If you're OP and you're considering clinical trials... well.... I hate to be the bearer of bad news, but you've got another problem. The compound you've described was also described in the scientific literature (back in the 90s) and it's in at least one patent application:
> https://patentimages.storage.googleapis.com/37/75/89/204db4e...
See claim 16 and "compound 102." So, unfortunately, fatal prior art exists. (On the bright side, those scientists arrived at exactly your hypothesis.)
My own hypothesis, that deuteration would be useful, is also in the patent literature: https://patents.google.com/patent/US10406155
As is the deuterated isopropoxy!
I'd suggest an alternative, but merely mentioning it here might constitute prior art. If you're interested in discussing, my email is in my profile.